How to take Toripalimab

Toripalimab (Toripalimab) As first-line treatment for nasopharyngeal carcinoma, the recommended dose is 240mg every three weeks until disease progression, unacceptable toxicity, or Up to 24 months;ToripalimabWhen treating recurrent nasopharyngeal carcinoma, melanoma, and urothelial cancer, the recommended dose is 3 mg/kg every two weeks until the disease worsens or unacceptable toxicity occurs.

Dose reduction of toripalimab is not recommended. In general, toripalimab should be discontinued for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue toripalimab for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions requiring systemic immunosuppressive therapy, or failure to reduce prednisone to 10 mg or less per day (or equivalent) within 12 weeks of steroid initiation.

Unless otherwise stated, toripalimab pharmacokinetic parameters are expressed as geometric means (Coefficient of variation[CV]%). Toripalimab concentrations increased nonlinearly over the dose range of 0.3-10 mg/kg every two weeks (the approved recommended dose for a 64-kg patient is 0.1-3.3 times 3 mg/kg), reaching a steady state at week 7. Following multiple doses at the approved recommended dose of 240 mg toripalimab in combination with cisplatin and gemcitabine every three weeks and 3 mg/kg toripalimab monotherapy every two weeks, the mean accumulation rate at maximum concentration (Cmax) was approximately 1.4 and the area under the serum concentration curve (AUC) was approximately 1.9.